Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nipro: SURELYZER PES-a
March 12, 2007
- Results of JPHC Study Announced
March 12, 2007
- Synergy NeuroStimulator from Medtronic, A New Option for Severe Chronic Pain: Dr Abe
March 12, 2007
- DSP to Start 3-Year Approach Run to Go Fully Global: Mr Miyatake
March 12, 2007
- GSK Launches New OTC Sleep Inducer
March 12, 2007
- Nippon Organon to Launch a Series of Major New Products: Mr van Eerd
March 12, 2007
- SELF-MEDICATION NEWS IN BRIEF
March 12, 2007
- Preminent Maintains Top Position: Rep Track Survey
March 12, 2007
- Pfizer Japan Needs Flat, Agile Organization: Mr Iwasaki
March 12, 2007
- DSM to Expand Its Business in Life Sciences
March 12, 2007
- BUSINESS NEWS IN BRIEF
March 12, 2007
- APDD Kicks Off Symposium on Microdosing Studies ―１―
March 12, 2007
- APDD Kicks Off Symposium on Microdosing Studies ―２―
March 12, 2007
- Post-Marketing Clinical Trials to Increase: JCROA Seminar
March 12, 2007
- R&D NEWS IN BRIEF
March 12, 2007
- Prefectural Health Policy Officials' Conference
March 12, 2007
- 4 NME-Based Drugs, 1 New Combination Recommended for Approval
March 5, 2007
- Norvasc Most Often Prescribed as 1st-Line: EPOCA Marketing
March 5, 2007
- Avastin Recommended for Approval
March 5, 2007
- No Jobs Will Be Cut in Japan: Mr Brennan of AstraZeneca
March 5, 2007
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…